Comparative Pharmacology
Head-to-head clinical analysis: FUROXONE versus PYRIMETHAMINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FUROXONE versus PYRIMETHAMINE.
FUROXONE vs PYRIMETHAMINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Furazolidone is a nitrofuran antimicrobial that inhibits bacterial monoamine oxidase and disrupts bacterial DNA synthesis by undergoing reduction by bacterial nitroreductases to reactive intermediates that cause DNA cross-linking and damage.
Pyrimethamine inhibits dihydrofolate reductase (DHFR) in the parasite, blocking the conversion of dihydrofolate to tetrahydrofolate, thereby inhibiting nucleic acid synthesis.
100 mg orally four times daily
For toxoplasmosis: 200 mg orally once, then 50-75 mg orally once daily for 4-6 weeks, plus sulfadiazine and folinic acid. For malaria prophylaxis: 25 mg orally once weekly.
None Documented
None Documented
Clinical Note
moderatePyrimethamine + Fesoterodine
"The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Pyrimethamine."
Clinical Note
moderatePyrimethamine + Artemether
"The risk or severity of QTc prolongation can be increased when Pyrimethamine is combined with Artemether."
Clinical Note
moderatePyrimethamine + Lumefantrine
"The risk or severity of QTc prolongation can be increased when Pyrimethamine is combined with Lumefantrine."
Clinical Note
moderateTerminal elimination half-life is approximately 1.5–2 hours; clinically, this supports dosing every 6 hours for sustained antibacterial effect.
Terminal elimination half-life is approximately 96 hours (range 80-123 hours) in adults with normal renal function; prolonged in renal impairment (up to 200 hours). This long half-life supports weekly dosing regimens.
Primarily renal (approximately 65%) as unchanged drug; biliary/fecal excretion accounts for about 35%.
Primarily renal (approximately 30% unchanged and 20-30% as metabolites); additional biliary/fecal elimination (20-30% as metabolites). Total urinary excretion of parent drug and metabolites accounts for 60-80% of dose.
Category C
Category D/X
Antibacterial/Antiprotozoal
Antimalarial / Antiprotozoal
Cyclophosphamide + Pyrimethamine
"The metabolism of Pyrimethamine can be decreased when combined with Cyclophosphamide."